Substrate for CYPs 3A4 and 3A5. No data pointing to clinical CYP-induction. One reference: authorised.

(To be edited, initial data ST OCT 04) Selective 5-HT-antagonist used as prophylaxis or treatment of postoperative nausea and nausea under chemotherapy ; 2-9 mg/d perorally or parenterally. Metabolized mainly by CYP 3A4. No instances of CYP-induction observed clinically. South African list: No data/avoid. French list: authorized

Uneventful use reported in 2 patients with acute porphyria.